Through the acquisition, the middle market private equity (PE) firm will work to expand Vibalogics capabilities to meet the industry’s demand through investments in additional process development and manufacturing capabilities.
The German contract development and manufacturing organization (CDMO) provides services for biopharmaceutical companies working to develop oncolytic viral therapies, gene therapies, and vaccines, specifically focusing on viruses, live bacteria, and aseptic processing.
Vibalogic’s 27,000 square-foot facility in Cuxhaven, Germany has four independent good manufacturing practice (GMP) production suites, and all laboratories meet BSL-2 standards.
David Anderson, general partner at Ampersand explained, “Given the exciting developments within the complex virus market this is an excellent time for an investor with deep experience in the viral vector contract manufacturing sector to partner with the company.”
Stefan Bayer, CEO of Vibalogics, said in a statement that with this partnership Vibalogics will also be able to strengthen and expand its position in the US and European markets.
Ampersand’s current portfolio includes other service providers such as Brammer Bio, Avista Pharma, Bioventus, MedPharm, and KeyBiologics.
